Literature DB >> 3355898

Increased platelet-fibrinogen affinity in patients with myeloproliferative disorders.

R Landolfi1, R De Cristofaro, M Castagnola, E De Candia, G D'Onofrio, G Leone, B Bizzi.   

Abstract

Patients with myeloproliferative disorders (MPD) are known to have some abnormalities of platelet glycoproteins (Gp). Quantitative changes of the Gp Ib, IIb-IIIa, and/or their glucidic content have been reported. Since the Gp IIb-IIIa complex plays a major role in fibrinogen binding by activated platelets, we measured the platelet fibrinogen affinity in nine patients with polycythemia vera (PV) and one subject with chronic myeloid leukemia (CML) by the aggregometric method of Marguerie. In all patients the Kd of the platelet fibrinogen reaction was significantly decreased as compared to controls, with evidence in two cases with PV of a heterogeneity of platelet-fibrinogen receptor sites. The measurement of 125I-labeled fibrinogen-platelet binding, performed in seven patients (five PV and two CML), showed receptor populations with increased (Kd1 = 0.58 + 0.3 X 10(7) mol/L) and normal affinity (Kd2 = 5.12 + 3.1 X 10(7) mol/L). These results demonstrate a heterogeneity of platelet-fibrinogen receptors in these patients and may explain the thrombotic diathesis of MPD subjects.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3355898

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  3 in total

Review 1.  The human platelet fibrinogen receptor: clinical and therapeutic significance.

Authors:  M Cahill; R Mistry; D B Barnett
Journal:  Br J Clin Pharmacol       Date:  1992-01       Impact factor: 4.335

2.  Allosteric equilibria in the binding of fibrinogen to platelets.

Authors:  R De Cristofaro; R Landolfi; E De Candia; M Castagnola; E Di Cera; J Wyman
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

3.  Effects of age, sex and the oral contraceptive on the platelet membrane fibrinogen binding site (glycoprotein IIb/IIIa).

Authors:  M Cahill; R Mistry; C Chapman; J K Wood; D B Barnett
Journal:  Br J Clin Pharmacol       Date:  1992-01       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.